You just read:

IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint

News provided by

AbbVie

Dec 05, 2017, 07:00 EST